COST-ENLIGHT strategic workshop on hadron (particle) therapy, CERN, Geneva, 3-4 May 2007.
This meeting was convened by COST (Co-operation in the Field of Scientific and Technical Research) and ENLIGHT (European Network for Research in Light-Ion Hadron Therapy) to review the current status of hadron therapy in Europe. The aims were to increase awareness of hadron therapy within the scientific community, to produce a document outlining the present and future prospects for this treatment modality and to bring together hadron therapy scientists and clinicians. Proton therapy offers the potential for therapeutic gain from dose distribution advantages when compared with photon therapy. Carbon ion therapy, by nature of its higher linear energy transfer (LET) and relative biological effectiveness (RBE), may further improve local control. A further potential benefit of carbon ion therapy is the ability to deliver hypofractionated radiotherapy. A further aim of this meeting was to commence preparation of a programme of work packages with a view to submitting an application for European Union funding within the FP7 programme. This comprises a series of seven work packages, which will be a focus for European collaboration.
Taylor
R E
RE
Swansea University, South West Wales Cancer Centre, Singleton Hospital, Swansea, UK. R.E.Taylor@Swansea.ac.uk
D002244:Carbon / Q000627:therapeutic use; D002648:Child; D004307:Dose-Response Relationship, Radiation; D004601:Elementary Particles / Q000627:therapeutic use*; D005060:Europe; D063193:Heavy Ion Radiotherapy; D006801:Humans; D018499:Linear Energy Transfer; D009369:Neoplasms / Q000532:radiotherapy*; D017785:Photons / Q000627:therapeutic use; D061766:Proton Therapy; D012062:Relative Biological Effectiveness
D002244:Carbon